4.6 Article

Chemical Chaperone TUDCA Preserves Cone Photoreceptors in a Mouse Model of Leber Congenital Amaurosis

期刊

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
卷 53, 期 7, 页码 3349-3356

出版社

ASSOC RESEARCH VISION OPHTHALMOLOGY INC
DOI: 10.1167/iovs.12-9851

关键词

-

资金

  1. Knights Templar Eye Foundation, Inc., Flower Mound, Texas
  2. E. Matilda Ziegler Foundation for the Blind, Inc., Darien, Connecticut
  3. Research to Prevent Blindness, Inc., New York, New York
  4. NIH [EY08123, EY019298, EY014800-039003]
  5. Foundation Fighting Blindness, Inc., Columbia, Maryland

向作者/读者索取更多资源

PURPOSE. Mutations in either retinoid isomerase (RPE65) or lecithin-retinol acyltransferase (LRAT) lead to Leber congenital amaurosis (LCA). By using the Lrat(-/-) mouse model, previous studies have shown that the rapid cone degeneration in LCA was caused by endoplasmic reticulum (ER) stress induced by S-opsin aggregation. The purpose of this study is to examine the efficacy of an ER chemical chaperone, tauroursodeoxycholic acid (TUDCA), in preserving cones in the Lrat(-/-) model. METHODS. Lrat(-/-) mice were systemically administered with TUDCA and vehicle (0.15 M NaHCO3) every 3 days from P9 to P28. Cone cell survival was determined by counting cone cells on flat-mounted retinas. The expression and subcellular localization of cone-specific proteins were analyzed by western blotting and immunohistochemistry, respectively. RESULTS. TUDCA treatment reduced ER stress and apoptosis in Lrat(-/-) retina. It significantly slowed down cone degeneration in Lrat(-/-) mice, resulting in a similar to 3-fold increase in cone density in the ventral and central retina as compared with the vehicle-treated mice at P28. Furthermore, TUDCA promoted the degradation of cone membrane-associated proteins by enhancing the ER-associated protein degradation pathway. CONCLUSIONS. Systemic injection of TUDCA is effective in reducing ER stress, preventing apoptosis, and preserving cones in Lrat(-/-) mice. TUDCA has the potential to lead to the development of a new class of therapeutic drugs for treating LCA. (Invest Ophthalmol Vis Sci. 2012;53:3349-3356) DOI:10.1167/iovs.12-9851

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据